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http://dx.doi.org/10.1016/j.ccr.2014.07.023SUMMARYOsteogenic sarcoma (OS) is a deadly skeletal malignancy whose cause is unknown. We report here a mouse
model of OS based on conditional expression of the intracellular domain of Notch1 (NICD). Expression of
the NICD in immature osteoblasts was sufficient to drive the formation of bone tumors, including OS, with
complete penetrance. These tumors display features of human OS; namely, histopathology, cytogenetic
complexity, and metastatic potential. We show that Notch activation combined with loss of p53 synergisti-
cally accelerates OS development in mice, although p53-driven OS is not Rbpj dependent, which demon-
strates a dual dominance of the Notch oncogene and p53 mutation in the development of OS. Using this
model, we also reveal the osteoblasts as the potential sources of OS.INTRODUCTION
Osteogenic sarcoma, also referred to as osteosarcoma (OS), is
the most common primary bone cancer, comprising approxi-
mately 20% of all bone tumors and 5% of pediatric tumors over-
all (Gorlick and Khanna, 2010). OS affects patients of all ages but
shows a substantially higher incidence in adolescents and young
adults. OS patients with metastases in lungs have poor 5-year
survival rates, on the order of 30% or less (Jawad et al., 2011).
Most cases of OS occur sporadically, and our understanding
of the molecular basis of the disease is still limited. Correspond-
ingly, there have been no substantial improvements in survival
rates over the past 3 decades, mostly owing to a lack of knowl-
edge of the driver gene mutations and cells of origin. In addition,
very few mouse models possessing a high frequency of OS are
currently available (Grigoriadis et al., 1993; Harvey et al., 1993;
Molyneux et al., 2010). Recently, Orkin and colleagues showed
that bone-specific disruption of Trp53 andRb leads to the forma-
tion of OS and mimics the human form of the disease (WalkleySignificance
HumanOS is an aggressivemesenchyme-derived tumor assoc
survival rate for OS patients has not improved substantially o
Notch gain of function as a cause of OS and advance our un
its cells of origin. Our study also supports the hypothesis that N
anism in cells of mesenchymal lineage such as committed oste
forms for probing cancer genetics and developing more effec
390 Cancer Cell 26, 390–401, September 8, 2014 ª2014 Elsevier Incet al., 2008), supporting the hypothesis that OS may arise from
mesenchymal-stem-cell-derived osteoblasts, the predominant
bone-forming cells.
Evolutionarily conserved signaling pathways such as the
Notch pathway are central mechanisms in embryogenesis,
postnatal homeostasis, and pathological conditions, including
tumorigenesis (Kopan and Ilagan, 2009). Notch proteins are
transmembrane receptors that are activated by physical interac-
tion with a transmembrane ligand on adjacent cells. Once a
Notch receptor is activated, it undergoes a series of intramem-
branous cleavages by proteolytic enzymes, including g-secre-
tase, that release the Notch intracellular domain (NICD). NICD
enters the nucleus and interacts with a transcriptional complex
comprising Rbpj and Mastermind-like proteins to regulate
expression of canonical targets such as the Hey and Hes family
of transcription factors. Notch receptor mutations have been
associated with several types of cancer, and current data sug-
gest that Notch can serve as either a tumor promoter or a tumor
suppressor in a context-dependent manner (Ranganathan et al.,iatedwith highmortality that affectsmostly adolescents. The
ver the past decades. Our findings reveal a critical role for
derstanding of the pathogenesis of this disease as well as
otch-activating mutations can act as an OS-initiating mech-
oblasts. Moreover, our OS models constitute valuable plat-
tive therapies for OS.
.
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Notch activation can stimulate proliferation of immature osteo-
blasts while inhibiting their differentiation into mature osteo-
blasts (Engin et al., 2008; Hilton et al., 2008; Zamurovic et al.,
2004; Zanotti et al., 2008). This gain-of-function phenotype is
reminiscent of osteoblastic tumors and is consistent with recent
findings showing that Notch signaling is upregulated in human
OS samples and that its inhibition in vitro and in immunodeficient
mice suppresses OS cell proliferation andmigration (Engin et al.,
2009; Tanaka et al., 2009). However, it is not known whether
Notch dysregulation is involved in the initiation and/or progres-
sion of OS.
A human Notch gain-of-function mutation was discovered in
cells derived from a patient with T cell acute lymphoblastic leu-
kemia (T-ALL) (Ellisen et al., 1991). Themutation, a chromosomal
7-chromosome 9 translocation, results in the expression of a
truncated NICD-like protein from NOTCH1, which encodes one
of four closely relatedmembers (Notch1–4) inmammals. Expres-
sion of this truncated protein predisposesmice to T cell leukemia
and recapitulates some aspects of the human disease (Robey
et al., 1996). A subsequent study found that more than 50%
of human T-ALLs have NOTCH1 gain-of-function mutations
involving the extracellular heterodimerization domain and/or
the C-terminal PEST domain, which regulates NICD degradation
(Weng et al., 2004). These missense mutations and/or frame-
shifting insertions or deletions result in ligand-independent
cleavage and accumulation of NICD in the nucleus and/or
NICD stabilization, inducing constitutively active Notch sig-
naling. Notch gain-of-function mutations have also been found
in several types of solid tumors, including lung cancer (Lawrence
et al., 2014; Westhoff et al., 2009). However, somatic Notch mu-
tations have yet to be identified in any types of mesenchyme-
derived rare cancers such as OS. Based on our and other recent
studies showing that activation of Notch signaling contributes to
the pathogenesis of human OS, we hypothesized that osteo-
blast-specific activation of the Notch signaling pathway may
be sufficient to initiate OS development.
RESULTS
NICD Expression in Committed Osteoblasts Induces
Malignant Bone Tumors that Mimic Human OS
We previously applied the conditional NICD allele to allow for the
tissue-restricted activation of this signaling pathway following
Cre expression in bone (Tao et al., 2010b). Rosa26NICD mice ex-
press NICD-IRES-GFP bicistronic messenger RNA (mRNA) from
the endogenous Rosa26 promoter, which enables monitoring of
NICD expression by detecting nuclear green fluorescent protein
(GFP) expression (Figure S1A available online). To achieve oste-
oblast-restricted expression, we utilized the Col1a1 2.3kb-Cre
transgenic mouse to direct Cre expression to committed osteo-
blasts. The conditional Rosa26NICD mice were bred to Col1a1
2.3kb-Cremice, and the resultingCol1a1 2.3kb-Cre; Rosa26NICD
(hereinafter, cNICD) progenies were followed longitudinally (Fig-
ure S1B). These mice were smaller than their siblings at a young
age and usually died of tumor-unrelated causes by 3 months of
age. However, 100% of the surviving cNICD mice eventually
caught up in growth to their littermates (Figure S1C) and sponta-
neously developed clinically manifested tumors between theCaages of 5 and 14 months (Figures 1A and 1B), demonstrating
complete penetrance in terms of tumor induction. Examination
of the mice by autopsy (Figures 1Aa–1Ad), X-ray imaging (Fig-
ures 1Ae–1Ah), and microscopic computed tomography (mi-
cro-CT) (Figures 1Ai–1Al) confirmed that only the bones were
affected, with no macroscopic abnormalities observed in any
other tissues. The cNICD mice had monostotic or polyostotic
bone tumors at all sites known to be affected in the human
disease. Histological examination revealed these to be osteosar-
coma or osteoma, a benign tumor that typically grows in the
human skull. The most frequent sites of osteoma in cNICD
mice were the maxilla and the zygomatic bone in the skull
(Figures S1D–S1E), followed by the radius and ulna in the fore-
limb (Figure S1F). Since osteosarcoma was responsible for the
deaths of most cNICD mice, all subsequent studies were per-
formed on Notch-induced osteosarcoma (hereinafter, NOS)
(Figure S1G).
The most frequent site of NOS was the femur, a major site for
human OS, followed by the forelimb/tibia/ribs and the hip and
spine (Figure 1C). A peak incidence in the long bones closely ap-
proximates that seen in human OS (Unni and Inwards, 2009). All
OS tumors in the 41 cNICD mice appeared remarkably similar in
morphology. Macroscopically, these tumors were firm, were
rounded, displayed a white-to-grayish cut surface, and often
contained areas of hemorrhage and cystic degeneration (Figures
1Aa–1Ad and S1H). In most cases, the underlying cortical bone
was disintegrated, and the medullary cavity was filled with tumor
cells (Figures 1Ae–1Al, S1H, and S1I).
Examination of individual NOS tumors from different animals
revealed uniform histopathological features: poorly differenti-
ated or undifferentiated hypercellular lesions with small deposits
of osteoid (bone matrix prior to calcification), scattered mitoses,
and clear invasion of the adjacent muscle and fat tissues, but not
nerves (Figures 2A and S2A). Together, these tumors displayed
histological characteristics typical of the most aggressive type
of human OS. Metastases are a major cause of death in patients
withOS,with the lung being themost common site.We observed
that a significant fraction of the OS lesions metastasized to lung
in approximately 40%of the examinedNOS-bearingmice. Some
metastatic lesions were detected macroscopically (Figures 2B
and S2B), whereas others could be only observed by micro-
scopy (Figures 2C and S2C). We did not detect metastases in
other organs. Expression of LacZ (Figures 2C and S2D) or nu-
clear GFP (Figures 2D and S2E) in these metastatic lung tumors
and primary tumors, but not in adjacent tissues, demonstrates
their osteoblastic origin. Thus, NOS closely resembles the hu-
man disease in terms of skeletal distribution, radiographic and
histologic features, and in the development of spontaneous
lung metastases. Therefore, our NOS model constitutes a valu-
able resource for the study of this cancer.
Cell Lines Derived from NOS Form Aggressive
High-Grade-type Tumors in Nude Mice
To further characterize these tumors, cell lines were derived
from primary tumors collected from a variety of locations from
different cNICD mice: one of the tumors (T14) was from the fe-
mur, one (T6) was from the tibia, one (T12) was from the hu-
merus, and one (T3) was from the scapula. All tumors yielded
fibroblastic-like cells, and immunostaining confirmed GFPncer Cell 26, 390–401, September 8, 2014 ª2014 Elsevier Inc. 391
Figure 1. Osteosarcoma in the cNICD Mice
(A) Necropsy photos (a–d), X-ray images (e–h), and micro-CT scans (i–l) of representative NOS in the femur (a, e, i), tibia (b, f, j), humerus (c, g, k), and vertebrae
(d, h, l), with white arrows pointing to the tumor.
(B) Kaplan-Meier tumor-free survival plots of cNICD (n = 50) and cNICD-RbpjcKO (n = 16) mice.
(C) Location and frequency of NOS in cNICD mice.
See also Figure S1.
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Notch Induces Osteogenic Sarcomaexpression in tumor cells (data not shown). The resulting cell
lines (called NOS-T3, NOS-T6, NOS-T12, and NOS-T14) were
fully immortalized. In order to investigate their tumorigenic
potential, we subcutaneously injected the NOS cells into immu-392 Cancer Cell 26, 390–401, September 8, 2014 ª2014 Elsevier Incnocompromised mice. All yielded substantial masses between
14 and 28 days. The resulting tumors closely resembled the
parental osteosarcomas and were poorly differentiated or undif-
ferentiated in nature (Figure 3A). Macroscopically, we did not.
Figure 2. Histopathological Features of Primary andMetastatic NOS
(A) Histology of representative NOS tumors stainedwith hematoxylin and eosin
(H&E) showing poorly differentiated OS with high cellularity and scattered
mitoses (white arrow, top left), and invasive infiltration of tumor cells into
surrounding muscle tissue (blue arrow, top right) and fat (blue arrow, bottom
left), but not nerves (bottom right). Scale bars, 50 mm.
(B) H&E-stained sections of representative lung metastatic OS mass (blue
arrow) showing high cellularity at highmagnification (right). Scale bars, 500 mm
(left) and 50 mm (right).
(C) Photo of a mouse lung lobe (left), which was harvested from a tritransgenic
mouse (Rosa26NICD; Col1a1 2.3kb-Cre; Rosa26LacZ) with whole-mount X-gal
staining shows a metastatic lesion (blue) that could not be detected macro-
scopically. Lung section counterstained with eosin (right) showed that LacZ
was only expressed in tumor cells (blue) but not in lung cells. Scale bars,
50 mm.
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Caobserve lung metastases in the transplanted mice, perhaps due
to the extremely rapid tumor development in these mice, which
may not allow for metastatic disease to become evident. We
also performed intratibial injection of NOS-T14 into nude mice
(Figure S3A) (n = 4), which induced the formation of masses in
the injected leg (Figures S3A and S3B). Altogether, the NOS
cell lines retained their ability to form high-grade-type osteosar-
coma in vivo.
Notch-Induced Tumors Exhibit Cytogenetic Complexity
with Recurrent Chromosomal Changes
To examine whether the Notch-induced tumors develop
genomic instability, we first performed spectral karyotyping
(SKY) on early passage cultures derived from six independent
primary tumors (T3, T6, T8, T12, T14, and T29). NOS primary
cells consistently presented high levels of aneuploidy, a charac-
teristic of human OS (Figure 3B). Chromosomal aberrations were
found in all samples as clonal and nonclonal nonrecurrent alter-
ations (Figure 3C) and also included nonrecurrent unbalanced
translocations (Figure S3C). As with human OS, none of the
translocations were recurrent. Two samples were found to be
nearly tetraploid, a state also observed in human OS (Fig-
ure S3D). We did not detect small chromosomes or fragments.
Next, we examined DNA copy number variants (CNV) using
CNV sequencing (Daines et al., 2009). Genomic imbalances
were detected in all tumors examined (T1, T6, T14, and T29),
with gains and losses ranging from segmental to focal, along
with microamplifications and deletions. The frequency of chro-
mosomal numerical abnormalities (CNAs) along each chromo-
some was calculated, revealing many recurrent events in the
primary tumors (Figures 3D and S3E). Somatic CNAs arising in
cancer can mediate rate limiting steps in tumorigenesis through
the gain of oncogene function and/or the loss of tumor suppres-
sors. The substantial changes included recurrent gains of chro-
mosomes 1, 6, 11, 12, and 15 and loss of chromosomes 7, 14,
and 17, all present in at least 50% of cases (Figure 3D). Some
of the gains identified in primary tumors—namely, chromosomes
6 and 11—are homologous to aberrations seen in human
chromosomes 7 and 17, respectively; these chromosomes are
frequently gained and recurrently altered in human OS (Yen
et al., 2009). Altogether, cytogenetic complexity with recurrent
chromosomal changes suggests that genomic instability plays
a key role in the development of Notch-induced tumors and
that the NOS lesions from cNICD mice share certain key down-
stream target genes and pathways for tumor initiation and
progression.
Rbpj Is Required for NOS Initiation in cNICD Mice
Our previous work showed that the osteosclerotic phenotype
manifested in cNICD mice was dramatically reversed when the
effect of the Notch gain of function was completely rescued by
breeding these mice on to a RbpjFlox/Flox background (Col1a1
2.3kb-Cre; Rosa26NICD ;RbpjFlox/Flox; hereinafter cNICD-
RbpjcKO) (Tao et al., 2010b). This suggests that the effects of(D) Immunofluorescent images stained with GFP (green) and DAPI (blue) in
lung metastatic tumor at low (top panels; scale bars, 200 mm) and high (bottom
panels; scale bars, 20 mm) magnifications.
See also Figure S2.
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Figure 3. Transplanted Tumors and
Genomic Instability in NOS
(A) Photos of representative nude mice (top left)
and subcutaneous tumors (bottom left) obtained
from the mice 14 days after a single subcutaneous
injection with the NOS-T12 cell line into their flanks
and hematoxylin-and-eosin-stained section of
primary OS T12 tumor (top right) and transplanted
tumors (bottom right) derived from the injected
mice. Scale bars, 50 mm.
(B) Representative SKY evaluation of harvested
cells from NOS-T12 cell line.
(C) Summary of SKY results for the indicated
tumors.
(D) Summary of percentages of gains (positive axis)
and losses (negative axis) for chromosomes 1–19,
as determined by analysis of CNV, compared
tumor to nontumor controls using whole genome
sequencing.
See also Figure S3.
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ical Notch signaling and are completely dependent on Rbpj func-
tion. We further investigated this by following these mice for a
longer period of time to detect OS formation. We observed
that the cNICD-RbpjcKO mice had a 0% incidence of bone tu-
mors by 450 days of age compared to all cNICD mice, which
developed bone tumors and died, on average, between 163
and 442 days (M = 290 days) (Figure 1B). These data suggest
that Rbpj and its targets are specifically responsible for initiating
the downstream events in the development of OS in vivo. Mech-
anistically, as previously shown, this pathological Notch gain of
function likely acts through its targets, including Hes and Hey
proteins, to positively regulate proproliferation factors such as
cyclin D1 and negatively regulate prodifferentiation factors
such as the Runx2 transcription factor (Engin et al., 2008; Hilton
et al., 2008; Zamurovic et al., 2004; Zanotti et al., 2008). Consis-
tent with this phenomenon, we found that Hey1 and Ccnd1were
continually upregulated to high levels in osteosarcomas from
cNICD mice, whereas Runx2 was significantly suppressed (Fig-
ure 4A). This is in agreement with recent reports showing that394 Cancer Cell 26, 390–401, September 8, 2014 ª2014 Elsevier Inc.cyclin D1 and Runx2 are significantly
involved in chromosomal instability and
tumorigenesis in mice (Casimiro et al.,
2012; Zaidi et al., 2007). Also, low level
of expression of Runx2 is frequently
observed in poorly differentiated OS
(Lengner et al., 2006; Mutsaers et al.,
2013). We examined the expression of
additional genes associated with human
OS and found reduced expression of
Trp53, a tumor suppressor gene. It is
interesting that we also found highly
decreased expression of Wnt inhibitory
factor 1 (Wif1), a recently identified tumor
suppressor gene in OS (Figure 4A).
Reduction of WIF1/Wif1 expression has
been associated with epigenetic silencing
in human OS and accelerated progres-
sion of OS in mice (Kansara et al., 2009).We did not detect increased expression of Cdkn1a and proto-
oncogenes Fos and Myc in NOS; overexpression of these
proto-oncogenes results in the development of osteogenic
tumors in mice and has been frequently detected in human OS
(Grigoriadis et al., 1993; Shimizu et al., 2010). Altogether, these
data support our hypothesis that Notch activation in committed
osteoblastic lineage cells may be a dominant mechanism in OS
initiation and progression.
Tumor Initiation and Progression in cNICD Mice Are
Accelerated by Loss of p53, but Loss of Rbpj Does
Not Prevent Tumorigenesis in p53 Null Mice
To assess the functional link between Notch and other mole-
cules associated with human OS such as p53, and the role of
Notch signaling in an established spontaneous model of OS,
we used genetically engineered mice harboring the p53 muta-
tion. In human OS, deficiency of p53 may serve as an OS driver,
given that a small percentage of patients with Li-Fraumeni syn-
drome carrying TP53 germline mutations develop OS (Li and
Fraumeni, 1969). In mice, several studies have demonstrated
Figure 4. Genetic Interaction of Notch Acti-
vation and p53 Loss of Function in OS
Development
(A) qRT-PCR analysis of genes associated with
human OS comparing Notch-induced OS with
normal bone (mean ± SD of three mice per group).
*p < 0.05 (Student’s t test).
(B) Kaplan-Meier survival plots of p53cKO,
p53cKO-cNICD, and p53cKO-RbpjcKO mice.
(C) Summary of genetic studies from each cohort
of mice. Mice without bone tumors were sacrificed
by 450 days of age in cohorts of p53cKO (8 of 35),
p53cKO-RbpjcKO (8 of 34), and cNICD-RbpjcKO
(16 of 16). The p values were calculated using
SigmaPlot through all pairwise multiple compari-
son procedures (Holm-Sidakmethod). fl, Flox; n.s.,
not significant.
See also Figure S4.
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dence of OS (Berman et al., 2008; Lengner et al., 2006; Lin
et al., 2009; Walkley et al., 2008). We observed that approxi-
mately 80% of Col1a1 2.3kb-Cre;Trp53Flox/Flox (hereinafter,
p53cKO) mice developed OS and died within 450 days (M =
370 days) (Figure 4B). Our results are consistent with a previous
report of this mousemodel (Lin et al., 2009). Compared to cNICD
mice, p53cKO mice began developing OS around 175 days, but
their progression was significantly slower (Figures 4B and 4C;
Figures S4A and S4B). To examine whether Notch gain of
function modulates the tumorigenic process driven by p53 inac-
tivation, we bred mice with the conditional NICD allele into an
osteoblast-specific p53 null background. Adult Col1a1 2.3kb-
Cre;Rosa26NICD; Trp53Flox/Flox (hereinafter, p53cKO-cNICD)
mice died between 91 and 234 days (M = 154 days), a time frame
significantly shorter than that observed in p53cKO or cNICD
mice (Figures 4B and 4C; Figures S4A and S4B). We observed
that 30 p53cKO-cNICD mice spontaneously developed OS
(Figures S4C–S4E). Malignant tumors from these mice closely
resembled NOS in cNICD mice with regard to macroscopicCancer Cell 26, 390–401, Sappearance (Figures S4Ea–S4Ed), skel-
etal location and radiographic features
(Figures S4C and S4Ee–S4El), rate of
lung metastasis (approximately 50% of
the examined mice) (Figures S4F–S4G),
and cellular morphology and distribution
of targeted GFP-positive cells (Fig-
ure S4H). Notably, we found a signifi-
cantly higher incidence of OS in the
axial skeleton; namely, the spine of the
p53cKO-cNICD mice (Figures S4C,
S4Ec, S4Eg, and S4Ek). Regarding treat-
ment of human patients with primary
tumors in the axial skeleton, the difficulty
in achieving complete surgical resection
contributes to the higher risk of local
recurrence and to a dismal survival
outcome (Jawad et al., 2011).
These data suggest that the p53 dele-
tion in the cNICD mice significantly influ-ences not only tumor initiation and progression but also a
preference for tumor location. On the other hand, to examine
whether the Rbpj or Notch canonical pathway is required for
tumorigenesis induced by p53 loss of function, we bred mice
carrying the Notch loss-of-function allele (RbpjFlox) on to the
osteoblast-specific p53 null background. Approximately 80%
of Col1a1 2.3kb-Cre;Trp53Flox/Flox;RbpjFlox/Flox (hereinafter,
p53cKO-RbpjcKO) mice died within 450 days (M = 378 days)
(Figures 4B and 4C). This cohort of mice spontaneously devel-
oped OS at a rate similar to that observed in the cohort of
p53cKO mice. The lack of a significant effect of loss of Rpbj
on a p53 null background could be due to the contribution
from Rbpj-independent or noncanonical Notch signaling. Non-
canonical signaling, primarily reported in Drosophila but still
poorly characterized in mammalian systems, may be activated
on a p53 null background (Kopan and Ilagan, 2009). Our data
show that Notch activation can independently initiate OS
and also act synergistically with loss of p53 in tumor progres-
sion, suggesting that the genetic interaction between Notch
and p53 promotes OS initiation and progression, althougheptember 8, 2014 ª2014 Elsevier Inc. 395
Figure 5. Expression Signature of NOS
Compared to p53-Loss-Induced OS
(A) Unsupervised hierarchical clustering of
mouse samples and heat map of RNA sequencing
data between NOS or p53-loss-induced tumors
(p53 OS)
(B) Ingenuity pathways analysis (IPA) of cancer
canonical signaling pathways associated with
significantly regulated genes (p < 0.05) in NOS
versus control. Significantly changed pathways
only observed in NOS are colored in light blue, and
those changed in both NOS and p53-induced OS
are shown in black.
(C) GSEA results for each of the indicated human
sarcomas for NOS primary malignant tumors. As-
terisks indicate statistical significance. NOM p val,
nominal p value.
See also Figure S5 and Tables S1, S2, S3, and S4.
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induced tumorigenesis in the context examined.
The Transcriptional Profile of Murine NOS Is Similar to
that of Human OS
To determine whether the similarity between NOS and OS ex-
tends to the transcriptomic level, we performed transcriptional
profiling analysis on NOS tumors and control bone samples
from wild-type mice. For this purpose, total RNAs were ex-
tracted from NOS tumors with similar histological features
from the same anatomic locations and then subjected to whole
transcriptome shotgun RNA sequencing (RNA-seq) analysis.
The samples generated an average of 48.8 ± 9.8 million map-
ped reads, which aligned to 14,495 ± 313 genes atR0.1 reads
per kilobase per million (RPKM). Since murine OS induced by
inactivation of p53 exhibits transcriptional profiles comparable
to those of human OS (Walkley et al., 2008), we compared
the expression profiles of tumors from both models. Clustering
analysis demonstrated a highly similar expression signature
among OS tumors induced by either Notch or loss of p53. An
unsupervised hierarchical clustering and heat map of the sam-
ples based on differentially expressed genes is representatively396 Cancer Cell 26, 390–401, September 8, 2014 ª2014 Elsevier Inc.shown in Figure 5A and Tables S1 and
S2. Ingenuity pathway analysis (IPA) of
the significantly regulated genes in the
mouse tumors compared to control
bone tissues highlighted that the two
types of tumors shared frequently altered
canonical signaling pathways, including
Wnt/beta-catenin, PTEN, PI3K/AKT, and
p53, as well as molecular mechanisms
of cancer (Figure 5B; Tables S3 and
S4). We also identified a few signaling
pathways differentially regulated in
NOS, including Notch, ERK/MAPK, and
Sonic Hedgehog, which play critical roles
in tumorigenesis and targeted therapies
(Dorsam and Gutkind, 2007; Ng and
Curran, 2011; Ranganathan et al.,
2011). In addition, RNA-seq analysis of
NOS tumors also revealed dysregulation of many components
in Notch and p53 signaling pathways, including Notch1,
Notch3, Il6, Cdkn2a, and Mdm2 (Figure S5A). Upregulation of
Notch receptors and other components of the Notch signaling
pathway were observed in several types of tumors, including
T-ALL and human OS (Engin et al., 2009; Koch and Radtke,
2007; Zender et al., 2013), although we do not know why
they are upregulated in NOS. Overall, we observed conserva-
tion and alteration in gene expression profiling from OS
induced by different drivers, which may provide insight into
the causative roles of either Notch gain of function or p53
loss of function in tumorigenesis.
To further explore the extent of the molecular similarity be-
tween human OS and the tumors induced by Notch activation
in mice, we compared our RNA-seq expression profiles of
NOS tumors with microarray-derived expression profiles from
several published human sarcoma expression data sets (Baird
et al., 2005; Henderson et al., 2005). To pursue this, we used
gene set enrichment analysis (GSEA) for interpreting gene
expression data. The murine tumor and control expression
data in units of FPKMwere normalized across samples and con-
verted to orthologous human genes. Enrichment of a given gene
Figure 6. Candidate Cells of Origin in Murine OS Models
(A) Kaplan-Meier survival plots of p53cKO, Osxp53cKO, and Prxp53cKOmice.
(B) Summary of genetic studies from each cohort of mice. The p values were
calculated using SigmaPlot (Holm-Sidak method). Asterisk indicates that there
is no significant difference (p = 0.153) between Osxp53cKO and Prxp53cKO.
(C) Summary of results from various genetic experiments. Loss of function of
p53 can induce OS at the early and late stages of MSC differentiation, but
Notch gain of function can only induce OS at a late stage.
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Notch Induces Osteogenic Sarcomaset was defined as having a p value < 0.05, a false discovery rate
(FDR) q value < 0.15, and a family-wise error rate (FWER) p
value < 0.05. Notably, primary NOS tumors showed a significant
enrichment for human OS, but not other human sarcomas,
across entire human tumor data sets from the Baird (Figure 5C)
and the Henderson data (data not shown).
To test whether mouse NOS tumors display altered expres-
sion of genes contained within the regions cytogenetically
defined in human OS, we used cytogenetic region enrichment
analysis (Walkley et al., 2008). We found that NOS displayed
significant enrichment at chromosomal region 4Q27-33 (Fig-
ure S5B). Additionally, to examine the extent of Notch activation
in human OS, we performed expression analysis of the estab-
lished Notch target geneHEY1 using a recently published micro-
array data set of 34 patient samples (Paoloni et al., 2009). It is
interesting that we found high HEY1 expression levels in a
portion of OS patients (Figure S5C), consistent with our previous
finding that Notch signaling is significantly upregulated in human
OS samples (Engin et al., 2009). Altogether, comparisons with
human tumor expression data highlight the similarity between
our mouse tumor model and human OS.CaCommitted Osteoblasts Are a Potential Source of Tumor
Cells in Osteosarcomagenesis
Noting that p53-loss-induced OS cells can arise from a variety of
stages of mesenchymal/osteoblast differentiation, we investi-
gated whether Notch activation at any stage, if expressed early,
could induce OS. Also, to compare the cells of origin in two mu-
rine models, Notch-induced and p53-loss-induced OS, we first
bred conditional Trp53Flox/Flox mice to either Prx1-Cre or Osx-
Cre mice. Prx1-Cre is widely expressed in mesenchymal stem
cells (MSC) or progenitors of the developing mammalian limbs
and head, whereas Osx-Cre is expressed in osteoblast precur-
sors in a transition stage from amultipotential/bipotential precur-
sor to the osteoblast lineage (Hilton et al., 2008; Walkley et al.,
2008). We observed that Prx1-Cre;Trp53Flox/Flox (hereinafter,
Prxp53cKO) mice (n = 9) developed OS or other tumors and
died within 393 days (M = 187 days) and that theOsx-Cre;Trp53-
Flox/Flox (hereinafter, Osxp53cKO) mice (n = 14) developed OS
and died within 320 days (M = 257 days) (Figure 6A). Our obser-
vations are consistent with previous reports of these mouse
models (Lin et al., 2009; Walkley et al., 2008). Compared to our
p53cKO mice, Prxp53cKO and Osxp53cKO mice developed
OS in a significantly shorter time frame (Figure 6B). This suggests
that OS-originating cells come from different stages of differen-
tiation, spanning early to late stages (Prx1-Cre > Osx-Cre >
Col1a1 2.3kb-Cre). We next investigated if NICD expression at
early stages of mesenchymal/osteoblast differentiation leads to
OS. We started by breeding the conditional Rosa26NICD mice
to either Prx1-Cre or Osx-Cre mice. It is surprising that no
Prx1-Cre;Rosa26NICD or Osx-Cre;Rosa26NICD pups were gener-
ated; all compound mutant embryos were abnormal and signifi-
cantly smaller compared to their littermates between embryonic
day (E)15.5 and E18.5, indicating that embryonic lethality (Fig-
ure 6C; data not shown). This suggests that expression of
NICDwas not tolerated or was toxic to cells at early stages, likely
due to suppression of MSC and progenitor differentiation. The
aforementioned results suggest that the two murine models
have common cells of origin in a population of committed oste-
oblasts, but the tumors induced by p53 loss have a wider range
of cellular origin (Figure 6C).
DISCUSSION
In this study, we model bone tumors in a genetically engineered
mouse and show that Notch activation in osteoblasts is sufficient
to initiate OS-like solid tumors recapitulating the defining fea-
tures of human OS. We also show a robust synergy between
Notch and p53 in tumorigenesis, indicating that Notch gain of
function greatly promotes progression of OS initiated by loss
of p53. Our transgenic models may provide valuable platforms
for probing cancer genetics and targeted therapeutics.
Expression of an oncogene in a Cre/loxP-based conditional
approach from the Rosa26 locus has been recently used for es-
tablishing a few mouse genetic models of cancers derived from
mesenchymal cells, including synovial sarcoma (SS) expressing
SS18-SSX2 (Haldar et al., 2007) and clear cell sarcoma (CCS) ex-
pressing EWS-ATF1 fusion protein (Straessler et al., 2013). We
applied the same targeted strategy and generated a NOSmouse
model by expressing the truncated protein NICD. A comparison
of the three models highlights fully penetrant tumorigenesisncer Cell 26, 390–401, September 8, 2014 ª2014 Elsevier Inc. 397
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of either SS18-SSX2 or EWS-ATF1, or NICD, in most cells in vivo
was toxic. The later onset of detectable malignant tumors in the
NOS mouse model relative to the SS and CCS models suggests
that additional hits may be required to foster tumor progression.
This may also represent a fundamental difference between
the transformation ability of the two types of oncogenes (translo-
cation-associated fusion versus truncated protein mutation).
Human cancers have been modeled in mice by cell-specific
expression of an activating truncated form of the Notch receptor
(Allen et al., 2011; Robey et al., 1996; Zender et al., 2013). Gain-
of-function mutations in NOTCH1 have been found in approxi-
mately 10% of cases of non-small-cell lung cancer (Lawrence
et al., 2013; Westhoff et al., 2009), the leading cause of can-
cer-related deaths. Notably, the Notch pathway is very active
in primary tumors and in cell lines from patients with liver cancer
and OS (Engin et al., 2009; Zender et al., 2013); however, Notch
mutations in low-frequency sarcoma remain underappreciated,
owing to scarce resources. It is interesting that somatic point
mutations in NOTCH1 have been recently found in most of the
21 tumor types analyzed in exome sequences from 4,742 human
cancers (Lawrence et al., 2014), suggesting that OS and other
types of cancers of mesenchymal origin may contain these
mutations.
In agreement with our model, Molyneux et al. showed that
osteoblast-specific expression of simian virus 40 large T antigen
(TAg) oncoprotein induces a range of osteoblastic lesions, from
benign osteoma to poorly differentiated OS with aggressive
metastatic features (Molyneux et al., 2010). Transgenic mice
expressing the oncogene c-fos developed osteoblastic and
chondroblastic OS tumors (Grigoriadis et al., 1993). Commonly,
oncogene-induced OS tumors have a long latency period. In our
mouse model, once visible, OS tumors grow rapidly and cause
death within a month, whereas osteomas grow very slowly,
frequently until death occurs. It is interesting that OS lesions
and osteomas seldom occur at the same anatomic site. It is
currently unknown why the same oncogene leads to two types
of tumors, but the transforming ability of Notch mutations may
be dependent on the cell types in which the gene is expressed.
This is evident from the fact that lung-specific expression of
Notch truncated protein induces only benign tumors but fails
to cause progression to lung cancer (Allen et al., 2011), whereas
liver-specific expression definitely results in malignant tumors
(Zender et al., 2013). Alternatively, we speculate that a different
hit induced by microenvironmental cues may promote different
downstream events, as seen in the TAg-inducedmodel, in which
additional loss of Prkar1a defines a subclass of high-grade-type
OS (Molyneux et al., 2010).
It is not unexpected that, in our p53-loss-driven OS model,
adding a ‘‘second hit’’ Notch activation mutation significantly
shortens tumor latency and aggressiveness, suggesting a critical
role for Notch signaling in OS progression. Other tumor models
based on Notch activation show similar results. Transgenic
mice expressing NICD specifically in T cells developed T cell leu-
kemia at a frequency of about 20% by 5 months of age (Robey
et al., 1996), but once a secondmutation was added, penetrance
of leukemia increased to 100% and tumor latency decreased to
2 months (Beverly and Capobianco, 2003). By supplementing
Myc expression, lung-specific expression of the Notch truncated398 Cancer Cell 26, 390–401, September 8, 2014 ª2014 Elsevier Incprotein enabled progression to lung cancer and metastases
(Allen et al., 2011). Additionally, in our cNICDmodel, p53 deletion
can dramatically accelerate tumor progression, suggesting that
p53 certainly constitutes a ‘‘second hit.’’ We propose that the
second hit is the factor that defines whether the tumor is benign
or malignant in the cNICD mice.
Using RNA-seq and IPA, we demonstrated a high degree of
conservation of changes in gene expression and signaling path-
ways, including Wnt, between that model and ours. Consistent
with a recent report (Mutsaers et al., 2013), we found that expres-
sion of Wnt-secreted antagonists, including Dkk1, Sost, and
Wif1, was significantly decreased in NOS, implicating Wnt acti-
vation in this context. This ‘‘Notch on-Wnt on’’ model has been
supported by a recent study showing that Notch activation in
cells of the osteoblastic lineage upregulates Wnt signaling
through suppression of Dkk1 and Sost (Canalis et al., 2013a).
Moreover, Wif1 is often epigenetically silenced in human OS,
and its targeted disruption accelerates OS development in
mice (Kansara et al., 2009). It is currently unknown whether the
epigenetic mechanism is accountable for Wif1 silencing in
NOS tumors and whether ectopic Wif1 expression inhibits
NOS cell growth. On the one hand, aberrant activation of the
WNT pathway is associated with numerous cancers, including
OS (Gorlick and Khanna, 2010). Elevated levels of nuclear local-
ized b-catenin, a critical mediator of the canonical Wnt pathway,
have been detected in the majority of OS tumors, as well as spo-
radic mutations of b-catenin (Wagner et al., 2011). On the other
hand, several studies suggest that downregulation of Wnt
signaling has an important role in OS pathogenesis (Cai et al.,
2010). So far, it is unclear whether up- or downregulation of
Wnt in vivo promotes OS formation and metastasis. In addition,
increasing evidence supports that Wnt and Notch signaling
interact with each other in both synergistic and antagonistic
manners in a context-dependent fashion (Tao et al., 2010a),
but it is not clear how they cooperate to initiate development
of OS tumor cells in the skeletal system.
Ages of patients with OS present a bimodal pattern, with the
first peak in adolescents and the second in the elderly (Jawad
et al., 2011). In the latter group, OS frequently arises under
chronic conditions, such as Paget’s disease, resulting from an
inflammatory process. Although our cNICDmice exhibit general-
ized osteosclerotic disease (Tao et al., 2010b), OS induction
does not require additional inflammation. Nonetheless, we found
that interleukin-6 (IL-6), a major mediator of inflammation, is
greatly increased in tumor tissues. Notably, IL-6 is a downstream
effector of Notch signaling, and its expression is mediated by
Hey1 in osteoblasts (Sethi et al., 2011). In addition, this cascade
of Notch1-Hey1-IL-6 released from osteoblasts directly acti-
vates osteoclastogenesis, which acts as a ‘‘vicious cycle’’ of
cancer osteolytic metastases (Tao et al., 2011). It is conceivable
that the severe osteolytic phenotype observed in the tumors
from cNICD mice may partially result from this vicious cycle.
Demarest et al. showed that expression of theNotch truncated
protein retains its requirement for maintenance of Notch-
induced T-ALL (Demarest et al., 2011). It will be interesting to
know whether continuous presence of NICD is obligatory for
NOS progression. This possibility warrants further investigation
for therapeutic purposes. A major challenge in OS management
is that no specific treatment is available for patients unsuitable.
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others have shown that inhibition of Notch signaling impedes hu-
man OS growth (Engin et al., 2009; Tanaka et al., 2009). How-
ever, this study shows that blockade of the Notch canonical
pathway in OS cells fails to halt tumor progression. We speculate
that the effect of Notch inhibition by g-secretase inhibitors (GSIs)
on OS growth emanates from the Notch noncanonical pathway
in a non-cell-autonomous fashion. Sethi et al. support our prop-
osition with their findings that cancer progression is impeded by
disrupting Notch signaling in normal neighboring cells rather
than in tumor cells (Sethi et al., 2011). By contrast, GSIs are
effective in blocking all Notch signals in tumor tissues, but their
application as anticancer drugs is unlikely, due to severe on-
target intestinal toxicity. Notably, newly developed humanized
antibodies against Notch ligands have been tested in mice
without limiting adverse effects (Tran et al., 2013). These findings
open new perspectives for the continued development of Notch
inhibitors for cancer therapy.
The cell of origin in human OS remains elusive. Much of our
understanding of cells of origin has been derived from the study
of OS mouse models generated by cell-type-specific loss of p53
(Berman et al., 2008; Lengner et al., 2006; Lin et al., 2009; Walk-
ley et al., 2008). Despite the difference in stages of Cre expres-
sion, all those models develop OS with clinical features very
similar to those of human OS, although latencies vary among
them. These data imply that the source of OS cells may be
MSC, osteoblast progenitors, or committed osteoblasts. We
generated NOS tumors within the immature osteoblast lineage
expressing Col1a1 2.3kb-Cre, suggesting that the committed
osteoblasts are favored candidate cells of origin in our model.
However, our data do not exclude Prx1-Cre- or Osx-Cre-ex-
pressing cells as potential sources of OS. Somatic mutations
may sporadically occur in only some of these cells at earlier
stages in human tissues. By breeding NICD mice with Prx1-
Cre or Osx-Cre mice, the Notch mutated protein is practically
present in all Cre-expressing cells and their lineage, thereby
potentially overburdening the organism and leading to embry-
onic death. Moreover, Prx1-Cre- or Osx-Cre-expressing cells
are not exclusive to the osteoblast lineage and may serve impor-
tant roles in other type of cells (Hilton et al., 2008; Walkley et al.,
2008). We cannot exclude that osteoblasts at a more differenti-
ated stage than cells expressing Col1a1 2.3kb-Cre are also
capable of initiating OS. Indeed, recent studies have shown
that Notch activation in different population cells at later stages
of osteoblastic differentiation results in overlapping, but distinct,
pathological bone phenotypes (Canalis et al., 2013b). Altogether,
these data support that committed osteoblasts are the favorite
candidate for cells of origin of OS.
In summary, we have revealed the critical role of Notch gain-
of-function mutations as a cause of OS in mice and advanced
our understanding of the genetic factors and signaling pathways
in pathogenesis of OS. Our study also warrants future screening
and identification of patients with mesenchyme-derived tumors
affected by mutations in Notch receptors, and in other compo-
nents of the pathway, for developing targeted treatment strate-
gies. Notably, by studying gain- and loss-of-function genetic
models in vivo, we have generated robust insights into how
signaling pathways such as Notch and p53 contribute to osteo-
sarcomagenesis, which may eventually provide a rational strat-Caegy for devising specific therapies targeting pathways leading
to OS. Finally, our study supports the hypothesis that Notch-
activating mutations can act as a common triggering mech-
anism in cells of mesenchymal origin such as committed
osteoblasts.
EXPERIMENTAL PROCEDURES
Animal Husbandry
Conditional knockout mice (RbpjFlox/Flox, Trp53Flox/Flox) and transgenic mice
(Col1a1 2.3kb-Cre, Rosa26NICD) have been previously described elsewhere
(Dacquin et al., 2002; Han et al., 2002; Jonkers et al., 2001; Murtaugh et al.,
2003). Prx1-Cre, Osx-Cre, and Rosa26LacZ reporter mice were purchased
from The Jackson Laboratory. Genotyping by PCR was performed as
described in the protocols supplied by the Jackson Laboratory (Trp53Flox/Flox,
Rosa26NICD, Prx1-Cre, Osx-Cre, and Rosa26LacZ), RIKEN BioResource Center
(RbpjFlox/Flox), and Mutant Mouse Regional Resource Center (Col1a1 2.3kb-
Cre). The mice were maintained on a hybrid 129 3 C57BL/6 background
and housed in a specific pathogen-free facility under controlled conditions
of light, temperature, and humidity. These studies were conducted in accor-
dance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals and approved by the Baylor College of Medicine (BCM)
Institutional Animal Care and Use Committee.
Radiography, Histological Analysis, Immunostaining, Quantitative
RT-PCR, Spectral Karyotyping Analysis, and Statistical Analyses
Mouse tumors were extracted after asphyxiation and were fixed overnight in
10% formalin solution prior to paraffin embedding. Skeletal preparations, radi-
ography, histological analysis, immunostaining, quantitative RT-PCR (qRT-
PCR), spectral karyotyping analysis, and statistical analyses are described in
the Supplemental Experimental Procedures.
RNA-Seq, Whole-Genome Sequencing, and Copy Number Variation
Analysis
Sequencing was performed on a HiSeq 2000 platform at the Human Genome
Sequencing Center of the BCM according to the manufacturer’s protocol. For
RNA RNA-sequencing, libraries were prepared according to the 20-deoxyuri-
dine, 50-triphosphate, or dUTP protocol. Illumina paired-end whole genome
shotgun libraries were prepared from tumor genomic DNA or non-tumor con-
trol tissue, which was used as a reference genome. For a detailed description
of sample preparation and bioinformatics analyses for high-throughput data,
see the Supplemental Experimental Procedures.
Human OS Gene Expression and GSEA
Human data from Paoloni et al. (2009) were downloaded from the Gene
Expression Omnibus gateway (http://www-ncbi-nlm-nih-gov.ezproxyhost.
library.tmc.edu/geo/) using accession number GSE16091. Human sarcoma
expression data sets were downloaded from the Baird and Henderson studies
(Baird et al., 2005; Henderson et al., 2005). Microarray data normalization
and statistical analyses were performed using the limma: Linear Models for
Microarray Data of the R statistical package. GSEA was performed as
described elsewhere (http://www.broad.mit.edu/gsea). We applied default al-
gorithm settings, and each data set underwent 1,000 permutations. A nominal
p value < 0.05 and an FDR q value < 0.15 were considered significant.
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The raw sequence data from RNA-seq and whole-genome sequencing gener-
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